<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="iso-abbrev">Hum Vaccin Immunother</journal-id><journal-id journal-id-type="publisher-id">KHVI</journal-id><journal-id journal-id-type="publisher-id">khvi20</journal-id><journal-title-group><journal-title>Human Vaccines &#x00026; Immunotherapeutics</journal-title></journal-title-group><issn pub-type="ppub">2164-5515</issn><issn pub-type="epub">2164-554X</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27841725</article-id><article-id pub-id-type="pmc">5215585</article-id><article-id pub-id-type="publisher-id">1183847</article-id><article-id pub-id-type="doi">10.1080/21645515.2016.1183847</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12&#x02013;15&#x000a0;years: Interim analysis of a large community-randomized controlled trial</article-title><alt-title alt-title-type="running-authors">M. LEHTINEN ET&#x000a0;AL.</alt-title><alt-title alt-title-type="running-title">Human Vaccines &#x00026; IMMUNOTHERAPEUTICS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lehtinen</surname><given-names>Matti</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref><xref ref-type="corresp" rid="an0001"/></contrib><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Tiina</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Apter</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="af0002"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hokkanen</surname><given-names>Mari</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Natunen</surname><given-names>Kari</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paavonen</surname><given-names>Jorma</given-names></name><xref ref-type="aff" rid="af0003"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pukkala</surname><given-names>Eero</given-names></name><xref ref-type="aff" rid="af0001"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Angelo</surname><given-names>Maria-Genalin</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zima</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>David</surname><given-names>Marie-Pierre</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Datta</surname><given-names>Sanjoy</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bi</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Struyf</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="af0004"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dubin</surname><given-names>Gary</given-names></name><xref ref-type="aff" rid="af0005"><sup>e</sup></xref></contrib><aff id="af0001"><label>a</label><institution>University of Tampere</institution>, Tampere, <country>Finland</country></aff><aff id="af0002"><label>b</label><institution>Family Federation of Finland</institution>, Helsinki, <country>Finland</country></aff><aff id="af0003"><label>c</label><institution>University of Helsinki</institution>, Helsinki, <country>Finland</country></aff><aff id="af0004"><label>d</label><institution>GSK Vaccines</institution>, Wavre, <country>Belgium</country></aff><aff id="af0005"><label>e</label><institution>GSK Vaccines</institution>, King of Prussia, PA, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001"><bold>CONTACT</bold> Matti Lehtinen <email xlink:href="llmale@uta.fi">llmale@uta.fi</email><institution>University of Tampere</institution>, POB 33014 Tampere, <country>Finland</country></corresp><fn><p>Supplemental data for this article can be accessed on the <ext-link ext-link-type="uri" xlink:href="http://www.tandfonline.com/khvi">publisher's website</ext-link>.</p></fn></author-notes><pub-date pub-type="collection"><month>12</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>14</day><month>11</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>11</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>12</volume><issue>12</issue><fpage seq="33">3177</fpage><lpage>3185</lpage><history><date date-type="received"><day>16</day><month>12</month><year>2015</year></date><date date-type="rev-recd"><day>24</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="description"> &#x000a9; Matti Lehtinen, Tiina Eriksson, Dan Apter, Mari Hokkanen, Kari Natunen, Jorma Paavonen, Eero Pukkala, Maria-Genalin Angelo, Julia Zima, Marie-Pierre David, Sanjoy Datta, Dan Bi, Frank Struyf, and Gary Dubin  <copyright-statement>--><copyright-statement>&#x000a9; 2016 The Author(s). Published with license by Taylor &#x00026; Francis</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="khvi-12-12-1183847.pdf"/><abstract><title>ABSTRACT</title><p>This community-randomized controlled trial was initiated to assess the overall and herd effects of 2 different human papillomavirus (HPV) immunization strategies in over 80,000 girls and boys aged 12&#x02013;15&#x000a0;y in 33 communities in Finland (ClinicalTrials.gov NCT00534638). Overall, 14,838 adolescents received HPV-16/18 vaccine (2,440 boys and 12,398 girls) and 17,338 received hepatitis-B virus (HBV) vaccine (9,221 boys and 8,117 girls). In an interim analysis, vaccine safety was assessed by active monitoring and surveillance via health registry linkage. Active monitoring showed that the HPV-16/18 vaccine has acceptable safety and reactogenicity in boys. In all study participants, the observed incidences (per 100,000 person-years) of serious adverse events (SAEs) possibly related to vaccination were 54.3 (95% Confidence Interval [CI]: 34.0&#x02013;82.1) in the HPV-16/18 group and 64.0 (95% CI: 43.2&#x02013;91.3) in the HBV group. During the follow-up period for this interim analysis, the most common new-onset autoimmune diseases (NOADs; with incidence rate &#x02265;15 per 100,000) in any group based on hospital discharge registry (HILMO) download were ulcerative colitis, juvenile arthritis, celiac disease, insulin-dependent diabetes mellitus (IDDM) and Crohn's disease. No increased NOAD incidences were observed in HPV-16/18 vaccine recipients compared to HBV vaccine recipients. In both the SAE possibly related- and HILMO-analyses, a lower incidence of IDDM was observed in HPV-16/18 vaccinees compared to HBV vaccinees (relative risks, 0.26 [95% CI: 0.03&#x02013;1.24] and 0.16 [95% CI: 0.03&#x02013;0.55], respectively).</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Human papillomavirus (HPV)</kwd><kwd>HPV-16/18 AS04-adjuvanted vaccine</kwd><kwd>adolescents</kwd><kwd>safety</kwd><kwd>autoimmune disease</kwd><kwd>insulin-dependent diabetes mellitus</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><ref-count count="35"/><page-count count="9"/></counts></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>Virus-like particle (VLP)-based vaccines against oncogenic, high-risk human papillomavirus (HPV) types 16 and 18 have been licensed in most countries, most recently including a 9-valent HPV vaccine (<italic>Gardasil 9</italic> [Merck &#x00026; Co. Inc.]).<xref rid="cit0001" ref-type="bibr"><sup>1-6</sup></xref> Basis for the licensure of <italic>Cervarix</italic>&#x000ae; (GSK Vaccines) and <italic>Gardasil</italic> (Merck &#x00026; Co., Inc.) was their acceptable safety profiles and vaccine efficacy (VE) against HPV types 16/18- or 6/11/16/18-related persistent genital infections and associated cervical intraepithelial neoplasia grade 2/3 (CIN2/3).<xref rid="cit0007" ref-type="bibr"><sup>7,8</sup></xref> Phase III trial VE estimates for the 2 vaccines appear similar against HPV types 16 and 18, but differ against CIN3+ irrespective of HPV type.<xref rid="cit0009" ref-type="bibr"><sup>9</sup></xref> While follow-up trials involving 22,000 young women (aged 16&#x02013;19&#x000a0;y at the time of first vaccination) are evaluating the long-term safety and efficacy of the 2 vaccines,<xref rid="cit0010" ref-type="bibr"><sup>10,11</sup></xref> recently launched national vaccination programs will provide data on rare safety outcomes albeit gradually.<xref rid="cit0012" ref-type="bibr"><sup>12-15</sup></xref></p><p>The HPV-16/18 vaccine is formulated with the AS04 Adjuvant System, containing 3-<italic>O</italic>-desacyl-4&#x02032;-monophosphoryl lipid A (MPL; 50&#x000a0;&#x000b5;g) adsorbed on aluminum salt (500&#x000a0;&#x000b5;g Al<sup>3+</sup>), which has been shown to widely induce T-helper and memory B cell responses,<xref rid="cit0016" ref-type="bibr"><sup>16</sup></xref> and probably is partially responsible for the wide cross-protectivity of the vaccine.<xref rid="cit0017" ref-type="bibr"><sup>17,18</sup></xref> However, a theoretical adverse event of this enhanced immunogenicity might be the induction (or promotion) of (ongoing) autoimmune processes. The overall and specific, with regard to new-onset autoimmune diseases (NOADs), safety profile of the HPV-16/18 AS04-adjuvanted vaccine has been acceptable in all ages studied and in combination with other routine vaccines.<xref rid="cit0019" ref-type="bibr"><sup>19-24</sup></xref> However, to date, safety data have been collected via conventional reporting of adverse events (AEs) and serious adverse events (SAEs) in clinical trials, and quantitative safety data from large cohorts of HPV-16/18 vaccinated adolescents and population-based health registers are sparse.</p><p>We report interim safety results for the HPV-16/18 AS04-adjuvanted vaccine administered to a large cohort of adolescents (ClinicalTrials.gov NCT00534638), with special emphasis on unique, quantitative population-based health care registry data on occurrence of NOADs post-vaccination. Study design and population characteristics have been described in a previous publication.<xref rid="cit0025" ref-type="bibr"><sup>25</sup></xref> The primary objective of the study is to demonstrate the effectiveness of the HPV-16/18 vaccine in reducing the prevalence of HPV-16/18 genital infection in females following community-based vaccination of girls and boys 12&#x02013;15&#x000a0;y old; these results will be reported in a future publication upon study and analysis completion.</p></sec><sec sec-type="other" id="s0002"><title>Results</title><sec id="s0002-0001"><title>Study population</title><p>A total of 80,272 adolescents (40,852 boys and 39,420 girls) in the 1992&#x02013;1995 birth cohorts were invited to participate in the study between October 2007 and April 2010, of whom 32,176 (11,661 boys and 20,515 girls) were enrolled and received at least one dose of study vaccine (<xref ref-type="fig" rid="f0001">Fig.&#x000a0;1</xref>). In all, 14,838 adolescents received the HPV-16/18 vaccine (2,440 boys and 12,398 girls) and 17,338 received the HBV vaccine (9,221 boys and 8,117 girls) at 12&#x02013;16&#x000a0;y of age. Virtually all subjects were white (Caucasian/European heritage; 99.0%) (Table&#x000a0;S1).
<fig id="f0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Subject disposition. N, number of subjects; SAE, serious adverse event; AE, adverse event.</p></caption><graphic xlink:href="khvi-12-12-1183847-g001"/></fig>
</p></sec><sec id="s0002-0002"><title>Active safety surveillance in males</title><p>The male diary card subset comprised 643 subjects who received HPV-16/18 vaccine and 1,047 who received HBV vaccine (<xref ref-type="fig" rid="f0001">Fig.&#x000a0;1</xref>). Compliance was high in returning general and local symptoms sheets (83.5% and 83.3% overall per dose, respectively, in the HPV-16/18 group and 88.6% and 88.5%, respectively, in the HBV group). Pain at the injection site was the most frequently solicited local symptom in both groups (reported during the 7-day period following 70.4% and 14.0% of HPV-16/18 and HBV vaccine doses, respectively); fatigue (31.1% and 21.5%), headache (23.9% and 18.8%) and myalgia (33.8% and 12.5%) were the most frequently solicited general symptoms. The rate of local and some general solicited symptoms (arthralgia, fatigue, headache and myalgia) appeared higher among boys who received HPV-16/18 vaccine compared to those who received HBV vaccine (<xref ref-type="fig" rid="f0002">Fig.&#x000a0;2</xref>).
<fig id="f0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>Incidence of solicited local and general symptoms reported during the 7-day post-vaccination period (Days 0&#x02013;6) following any vaccine dose (male study participants in the male diary card subset, total vaccinated cohort). *Occurrence of rash and urticaria within 30&#x000a0;minutes following vaccination.</p></caption><graphic xlink:href="khvi-12-12-1183847-g002"/></fig>
</p><p>Unsolicited AEs reported in the month following any vaccine dose were comparable between HPV-16/18- and HBV-vaccinated boys (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). During the 30-day post-vaccination period, 24.4% and 19.3% of boys reported at least one unsolicited symptom after 10.1% and 7.6% of doses in the HPV-16/18 and HBV groups, respectively. Unsolicited AEs considered by the investigator to be possibly related to vaccination were reported by 1.9% and 1.8% of boys in the HPV-16/18 and HBV groups, respectively, after 0.7% and 0.6% of doses.
<table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Active safety surveillance from Month 0&#x02013;Month 12 (male dairy card subset, total vaccinated cohort). Incidence of unsolicited symptoms (most frequent symptoms listed), serious adverse events, medically significant conditions and new-onset autoimmune diseases.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th colspan="2" align="center">HPV-16/18 vaccine (N = 643)<hr/></th><th colspan="2" align="center">HBV vaccine (N = 1047)<hr/></th></tr><tr><th align="left">&#x000a0;</th><th align="center">n</th><th align="center">% (95% CI)</th><th align="center">n</th><th align="center">% (95% CI)</th></tr></thead><tbody><tr><td colspan="5" align="center"><italic><bold>Within 30 d (Days 0&#x02013;29) following any vaccine dose</bold></italic></td></tr><tr><td align="left">Unsolicited symptoms</td><td align="char" char=".">157</td><td align="char" char="(">24.4 (21.1&#x02013;27.9)</td><td align="char" char=".">202</td><td align="char" char="(">19.3 (16.9&#x02013;21.8)</td></tr><tr><td align="left">&#x02003;Nasopharyngitis</td><td align="char" char=".">33</td><td align="char" char="(">5.1 (3.6&#x02013;7.1)</td><td align="char" char=".">17</td><td align="char" char="(">1.6 (0.9&#x02013;2.6)</td></tr><tr><td align="left">&#x02003;Headache</td><td align="char" char=".">23</td><td align="char" char="(">3.6 (2.3&#x02013;5.3)</td><td align="char" char=".">16</td><td align="char" char="(">1.5 (0.9&#x02013;2.5)</td></tr><tr><td align="left">Oropharyngeal pain</td><td align="char" char=".">15</td><td align="char" char="(">2.3 (1.3&#x02013;3.8)</td><td align="char" char=".">32</td><td align="char" char="(">3.1 (2.1&#x02013;4.3)</td></tr><tr><td align="left">&#x02003;Pyrexia</td><td align="char" char=".">17</td><td align="char" char="(">2.6 (1.5&#x02013;4.2)</td><td align="char" char=".">21</td><td align="char" char="(">2.0 (1.2&#x02013;3.0)</td></tr><tr><td align="left">&#x02003;Upper RTI</td><td align="char" char=".">13</td><td align="char" char="(">2.0 (1.1&#x02013;3.4)</td><td align="char" char=".">3</td><td align="char" char="(">0.3 (0.1&#x02013;0.8)</td></tr><tr><td align="left">&#x02003;Vaccine-related</td><td align="char" char=".">12</td><td align="char" char="(">1.9 (1.0&#x02013;3.2)</td><td align="char" char=".">19</td><td align="char" char="(">1.8 (1.1&#x02013;2.8)</td></tr><tr><td colspan="5" align="center"><italic><bold>Up to Month 12 after first vaccine dose</bold></italic></td></tr><tr><td align="left">Serious adverse events</td><td align="char" char=".">8</td><td align="char" char="(">1.2 (0.5&#x02013;2.4)</td><td align="char" char=".">21</td><td align="char" char="(">2.0 (1.2&#x02013;3.0)</td></tr><tr><td align="left">&#x02003;Vaccine-related</td><td align="char" char=".">1</td><td align="char" char="(">0.2 (0.0&#x02013;0.9)</td><td align="char" char=".">1</td><td align="char" char="(">0.1 (0.0&#x02013;0.5)</td></tr><tr><td align="left">Medically significant conditions</td><td align="char" char=".">47</td><td align="char" char="(">7.3 (5.4&#x02013;9.6)</td><td align="char" char=".">76</td><td align="char" char="(">7.3 (5.8&#x02013;9.0)</td></tr><tr><td align="left">New onset autoimmune diseases</td><td align="char" char=".">1</td><td align="char" char="(">0.2 (0.0&#x02013;0.9)</td><td align="char" char=".">1</td><td align="char" char="(">0.1 (0.0&#x02013;0.5)</td></tr></tbody></table><table-wrap-foot><fn id="t1fn0001"><p>N, total number of male subjects; n (%), number (percentage) of male subjects with at least one symptom; HPV vaccine, HPV-16/18 AS04-adjuvanted vaccine; HBV, hepatitis B virus vaccine; RTI, respiratory tract infection.</p></fn></table-wrap-foot></table-wrap>
</p><p>From Dose 1 to Month 12, in male study participants in the diary card subset, the proportion of boys with SAEs, SAEs possibly related to vaccination, NOAD and medically significant conditions (MSCs) were within the same range in both vaccine groups (<xref ref-type="table" rid="t0001">Table&#x000a0;1</xref>). SAEs were reported for 1.2% and 2.0% of boys who received HPV-16/18 and HBV vaccines, respectively. Two SAEs (IDDM and juvenile arthritis [JA]) were considered possibly related to vaccination by the investigator (blinded to treatment allocation). MSCs were reported by 7.3% of boys for both vaccines. These were considered possibly related to vaccination by the investigator in 3 boys (0.5%) who received HPV-16/18 vaccine and 1 boy (0.1%) who received HBV vaccine (concussion, IDDM, JA and oropharyngeal pain; blinded to treatment allocation). One boy in each group reported an NOAD (IDDM and JA). Both events were reported as SAEs and were considered possibly related to vaccination by the investigator.</p><p>From Dose 1 to Month 12, in male study participants with active follow-up, SAEs were reported by 2.4% of boys who received HPV-16/18 vaccine and 2.0% of boys who received HBV vaccine. Possible relationship of SAEs with vaccination could not be excluded in 4 boys (0.2%) who received HPV-16/18 vaccine and 1 boy (0.1%) who received HBV vaccine (abdominal pain, ulcerative colitis, IDDM and JA; blinded to treatment allocation).</p></sec><sec id="s0002-0003"><title>SAEs considered possibly related to vaccination in all study participants based on active and passive surveillance</title><p>During the follow-up period for this interim analysis, the observed incidence rates (per 100,000 person-years) for SAEs considered possibly related to vaccination according to the investigator in all study participants based on active and passive surveillance were 54.3 (95% confidence interval [CI]: 34.0&#x02013;82.1) in the HPV-16/18 group and 64.0 (95% CI: 43.2&#x02013;91.3) in the HBV group. The most common SAEs considered possibly related to vaccination by the investigator (with incidence rate &#x02265;10 per 100,000 person-years in any group) were ulcerative colitis, Crohn's disease, and IDDM. No deaths had been reported at the time of this interim analysis.</p><p>The incidence rates of possibly vaccine-related SAEs were 52.8 (95% CI: 31.3&#x02013;83.4) and 72.3 (95% CI: 41.3&#x02013;117.3) in the HPV-16/18 and HBV groups, respectively, for female study participants (based on spontaneous reporting and Care Register for Social Welfare and Health Care [HILMO] data) and 62.1 (95% CI: 16.9&#x02013;158.9) and 56.6 (95% CI: 30.9&#x02013;94.9), respectively, for male study participants (based on active surveillance in a subset of subjects as well as spontaneous reporting and HILMO data for all subjects).</p></sec><sec id="s0002-0004"><title>New-onset autoimmune diseases in all study participants</title><p>During the follow-up period for this interim analysis in all study participants, the most common NOADs (with incidence rate &#x02265;15 per 100,000 in any group based on the HILMO linkage) were ulcerative colitis (25.0 and 29.0 cases per 100,000 person years in the HPV-16/18 and HBV groups, respectively), juvenile arthritis (22.2 and 26.6 cases per 100,000 person years, respectively), celiac disease (16.7 and 26.6 cases per 100,000 person years, respectively), IDDM (8.3 and 50.7 cases per 100,000 person years, respectively), and Crohn's disease(8.3 and 16.9 cases per 100,000 person years, respectively). Of note, no cases of Guillain-Barr&#x000e9; syndrome were observed, and other NOADs were found only occasionally in both vaccine groups. In terms of numbers of cases, IDDM was the most common NOAD diagnosis identified in the HILMO linkage (3 cases in the HPV-16/18 group and 21 in the HBV group). Almost all the 95% CIs of relative risk (RR) estimates for the incident NOAD cases in the HPV-16/18 group as compared to the HBV group included unity (<xref ref-type="fig" rid="f0003">Fig.&#x000a0;3</xref>), with the exception of IDDM (RR: 0.16, 95% CI: 0.03&#x02013;0.55). A decreased relative risk of IDDM was observed both for females (2&#x000a0;vs. 7 cases; RR: 0.19, 95% CI: 0.02&#x02013;0.97) and males (1&#x000a0;vs. 14 cases; RR: 0.27, 95% CI: 0.01&#x02013;1.8) (Table&#x000a0;S2).
<fig id="f0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Estimated relative risk of the occurrence of new-onset autoimmune disease (NOADs) with 95% confidence interval, classified by MedDRA primary system organ class and preferred term, during the entire study period (all study participants, total vaccinated cohort). Dots represent point estimates. NOADS which occur in only one group remain blinded and are therefore not shown in this figure.</p></caption><graphic xlink:href="khvi-12-12-1183847-g003"/></fig>
</p><p>The incidences of the most common NOADs identified by the HILMO linkage (i.e., medical history-confirmed) and by SAE reporting are shown in <xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>. More cases were recorded in the HILMO registry (<xref ref-type="table" rid="t0002">Table&#x000a0;2</xref>).
<table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Incidence (per 100,000 person years) and relative risk of major NOADs in all study participants (total vaccinated cohort) based on active and passive surveillance and registry analysis.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/><col width="86.4pt" align="left"/></colgroup><thead><tr><th align="left">&#x000a0;</th><th align="center">&#x000a0;</th><th colspan="2" align="center">HPV-16/18 vaccine All<hr/></th><th colspan="2" align="center">HBV vaccine All<hr/></th><th colspan="3" align="center">Relative risk (HPV/HBV) (95% CI)<hr/></th></tr><tr><th align="left">Category</th><th align="center">Case identification</th><th align="center">No. cases</th><th align="center">Incidence (10<sup>5</sup>) (95% CI)</th><th align="center">No. cases</th><th align="center">Incidence (10<sup>5</sup>) (95% CI)</th><th align="center">All</th><th align="center">Female<sup>d</sup></th><th align="center">Male<sup>d</sup></th></tr></thead><tbody><tr><td rowspan="3" align="left">Henoch-Schonlein purpura</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">2</td><td align="char" char="(">5.6 (0.7&#x02013;20.1)</td><td align="char" char=".">2</td><td align="char" char="(">4.8 (0.6&#x02013;17.5)</td><td align="char" char="(">1.15 (0.08&#x02013;15.87)</td><td align="char" char="(">1.3 (0.07&#x02013;76.47)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">2</td><td align="char" char="(">9.3 (1.1&#x02013;33.7)</td><td align="char" char=".">1</td><td align="char" char="(">4.0 (0.1&#x02013;22.2)</td><td align="char" char="(">2.34 (0.12&#x02013;138.23)</td><td align="char" char="(">1.31 (0.07&#x02013;77.42)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">2.5 (0.1&#x02013;13.7)</td><td align="char" char=".">1</td><td align="char" char="(">2.1 (0.1&#x02013;11.9)</td><td align="char" char="(">1.16 (0.01&#x02013;90.77)</td><td align="char" char="(">0.65 (0.01&#x02013;50.96)</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">Idiopathic thrombocytopenic purpura</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">8.3 (1.7&#x02013;24.4)</td><td align="char" char=".">4</td><td align="char" char="(">9.7 (2.6&#x02013;24.7)</td><td align="char" char="(">0.86 (0.13&#x02013;5.10)</td><td align="char" char="(">0.97 (0.11&#x02013;11.64)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">4.7 (0.1&#x02013;26.0)</td><td align="char" char=".">2</td><td align="char" char="(">8.0 (1.0&#x02013;28.8)</td><td align="char" char="(">0.59 (0.01&#x02013;11.25)</td><td align="char" char="(">0.33 (0.01&#x02013;6.3)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">2.5 (0.1&#x02013;13.7)</td><td align="char" char=".">1</td><td align="char" char="(">2.1 (0.1&#x02013;11.9)</td><td align="char" char="(">1.16 (0.01&#x02013;90.77)</td><td align="char" char="(">0.65 (0.01&#x02013;50.96)</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">Autoimmune thyroiditis</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">8.3 (1.7&#x02013;24.4)</td><td align="char" char=".">1</td><td align="char" char="(">2.4 (0.1&#x02013;13.5)</td><td align="char" char="(">3.45 (0.28&#x02013;181.16)</td><td align="char" char="(">1.94 (0.16&#x02013;102.07)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">14.0 (2.9&#x02013;40.9)</td><td align="char" char=".">1</td><td align="char" char="(">4.0 (0.1&#x02013;22.2)</td><td align="char" char="(">3.51 (0.28&#x02013;184.51)</td><td align="char" char="(">1.97 (0.16&#x02013;103.34)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="center">*1*</td><td align="center">na</td><td align="center">*1*</td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">Celiac disease</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">6</td><td align="char" char="(">16.7 (6.1&#x02013;36.3)</td><td align="char" char=".">11</td><td align="char" char="(">26.6 (13.3&#x02013;47.5)</td><td align="char" char="(">0.63 (0.19&#x02013;1.85)</td><td align="char" char="(">0.56 (0.15&#x02013;1.93)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">14.0 (2.9&#x02013;40.9)</td><td align="char" char=".">8</td><td align="char" char="(">31.9 (13.8&#x02013;62.8)</td><td align="char" char="(">0.44 (0.08&#x02013;1.83)</td><td align="char" char="(">0.39 (0.06&#x02013;2.02)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="center">&#x02014;</td><td align="center">na</td><td align="char" char=".">&#x02014;</td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">Ulcerative colitis</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">9</td><td align="char" char="(">25.0 (11.4&#x02013;47.5)</td><td align="char" char=".">12</td><td align="char" char="(">29.0 (15.0&#x02013;50.6)</td><td align="char" char="(">0.86 (0.32&#x02013;2.23)</td><td align="char" char="(">1.13 (0.29&#x02013;5.28)</td><td align="char" char="(">0.96 (0.1&#x02013;4.8)</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">6</td><td align="char" char="(">28.0 (10.3&#x02013;61.0)</td><td align="char" char=".">9</td><td align="char" char="(">35.9 (16.4&#x02013;68.1)</td><td align="char" char="(">0.78 (0.23&#x02013;2.46)</td><td align="char" char="(">0.82 (0.18&#x02013;4.13)</td><td align="char" char="(">0.77 (0.02&#x02013;6.86)</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="char" char=".">5</td><td align="char" char="(">12.3 (4.0&#x02013;28.8)</td><td align="char" char=".">3</td><td align="char" char="(">6.4 (1.3&#x02013;18.7)</td><td align="char" char="(">1.93 (0.37&#x02013;12.41)</td><td align="char" char="(">1.3 (0.19&#x02013;14.35)</td><td align="char" char="(">3.84 (0.05&#x02013;301.44)</td></tr><tr><td rowspan="3" align="left">Crohn's disease</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">8.3 (1.7&#x02013;24.4)</td><td align="char" char=".">7</td><td align="char" char="(">16.9 (6.8&#x02013;34.8)</td><td align="char" char="(">0.49 (0.08&#x02013;2.16)</td><td align="char" char="(">1.94 (0.16&#x02013;102.07)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">2</td><td align="char" char="(">9.3 (1.1&#x02013;33.7)</td><td align="char" char=".">5</td><td align="char" char="(">19.9 (6.5&#x02013;46.5)</td><td align="char" char="(">0.47 (0.04&#x02013;2.86)</td><td align="char" char="(">1.31 (0.07&#x02013;77.42)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">2.5 (0.1&#x02013;13.7)</td><td align="char" char=".">5</td><td align="char" char="(">10.7 (3.5&#x02013;24.9)</td><td align="char" char="(">0.23 (0.00&#x02013;2.07)</td><td align="char" char="(">0.65 (0.01&#x02013;50.96)</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">IDDM</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">8.3 (1.7&#x02013;24.4)</td><td align="char" char=".">21</td><td align="char" char="(">50.7 (31.4&#x02013;77.5)</td><td align="char" char="(">0.16 (0.03&#x02013;0.55)</td><td align="char" char="(">0.19 (0.02&#x02013;0.97)</td><td align="char" char="(">0.27 (0.01&#x02013;1.8)</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">3</td><td align="char" char="(">14.0 (2.9&#x02013;40.9)</td><td align="char" char=".">8</td><td align="char" char="(">31.9 (13.8&#x02013;62.8)</td><td align="char" char="(">0.44 (0.08&#x02013;1.83)</td><td align="char" char="(">0.26 (0.02&#x02013;1.6)</td><td align="char" char="(">1.28 (0.02&#x02013;15.93)</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="char" char=".">2</td><td align="char" char="(">4.9 (0.6&#x02013;17.8)</td><td align="char" char=".">9</td><td align="char" char="(">19.2 (8.8&#x02013;36.4)</td><td align="char" char="(">0.26 (0.03&#x02013;1.24)</td><td align="char" char="(">0.16 (0&#x02013;1.64)</td><td align="char" char="(">0.77 (0.02&#x02013;6.86)</td></tr><tr><td rowspan="3" align="left">Juvenile arthritis</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">8</td><td align="char" char="(">22.2 (9.6&#x02013;43.8)</td><td align="char" char=".">11</td><td align="char" char="(">26.6 (13.3&#x02013;47.5)</td><td align="char" char="(">0.84 (0.29&#x02013;2.28)</td><td align="char" char="(">0.49 (0.14&#x02013;1.6)</td><td align="char" char="(">2.56 (0.21&#x02013;22.31)</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">7</td><td align="char" char="(">32.7 (13.1&#x02013;67.3)</td><td align="char" char=".">11</td><td align="char" char="(">43.8 (21.9&#x02013;78.4)</td><td align="char" char="(">0.75 (0.25&#x02013;2.11)</td><td align="char" char="(">0.41 (0.11&#x02013;1.42)</td><td align="char" char="(">2.56 (0.21&#x02013;22.33)</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="center">*3*</td><td align="center">na</td><td align="center">*3*</td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr><tr><td rowspan="3" align="left">Rheumatoid arthritis</td><td align="left">Registry all<xref rid="t2fn0001" ref-type="fn"><sup>a</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">2.8 (0.1&#x02013;15.5)</td><td align="char" char=".">2</td><td align="char" char="(">4.8 (0.6&#x02013;17.5)</td><td align="char" char="(">0.58 (0.01&#x02013;11.05)</td><td align="char" char="(">0.32 (0.01&#x02013;6.22)</td><td align="center">na</td></tr><tr><td align="left">Registry 12&#x000a0;m<xref rid="t2fn0002" ref-type="fn"><sup>b</sup></xref></td><td align="char" char=".">1</td><td align="char" char="(">4.7 (0.1&#x02013;26.0)</td><td align="char" char=".">1</td><td align="char" char="(">4.0 (0.1&#x02013;22.2)</td><td align="char" char="(">1.17 (0.01&#x02013;91.96)</td><td align="char" char="(">0.66 (0.01&#x02013;51.51)</td><td align="center">na</td></tr><tr><td align="left">SAE possibly-related<xref rid="t2fn0003" ref-type="fn"><sup>c</sup></xref></td><td align="center">*1*</td><td align="center">na</td><td align="center">*1*</td><td align="center">na</td><td align="center">na</td><td align="center">na</td><td align="center">na</td></tr></tbody></table><table-wrap-foot><fn id="t2fn0001"><label>a</label><p>health register-identified, medical record-confirmed cases diagnosed post 1<sup>st</sup> vaccine dose during the entire study period (all study participants, total vaccinated cohort); 35,992 and 41,401 follow-up years in the HPV-16/18 and HBV groups, respectively</p></fn><fn id="t2fn0002"><label>b</label><p>health register-identified, medical record-confirmed cases diagnosed within 12&#x000a0;months after last vaccination (all study participants, total vaccinated cohort); 21,422 and 25,097 follow-up years in the HPV-16/18 and HBV groups, respectively</p></fn><fn id="t2fn0003"><label>c</label><p>SAE cases considered possibly related to vaccination during the entire study period (all study participants, total vaccinated cohort); 40,552 and 46,890 follow-up years in the HPV-16/18 and HBV groups, respectively.</p></fn><fn id="t2fn0004"><p>*n*, total number of cases reported, information is blinded since the study is ongoing</p></fn><fn id="t2fn0005"><p>HPV-16/18 vaccine, HPV-16/18 AS04-adjuvanted vaccine; HBV, hepatitis B virus vaccine; IDDM, insulin-dependent diabetes mellitus&#x000a0;; na, not available; 12&#x000a0;m, 12&#x000a0;months; 95% CI, 95% confidence interval</p></fn></table-wrap-foot></table-wrap>
</p></sec><sec id="s0002-0005"><title>Pregnancies in all female study participants</title><p>A total of 174 pregnancies had been spontaneously reported at the time of this interim analysis (100 in girls who received HPV-16/18 vaccine and 74 in girls who received HBV vaccine). The majority of pregnancies resulted in elective termination with no apparent congenital anomaly (60 [60.0%; 95% CI: 49.7&#x02013;69.7] and 52 [70.3%; 95% CI: 58.5&#x02013;80.3] for the 2 vaccines, respectively) or in a live infant (no premature birth) with no apparent congenital anomaly (30 [30.0%; 95% CI: 21.2&#x02013;40.0] and 20 [27.0%; 95% CI: 17.4&#x02013;38.6], respectively). Spontaneous abortions before 22&#x000a0;weeks of gestation (with no apparent congenital anomaly) were reported in 7 girls who received HPV-16/18 vaccine versus 2 girls who received HBV vaccine (7.0% [95% CI: 2.9&#x02013;13.9] vs. 2.7% [95% CI: 0.3&#x02013;9.4]; RR: 2.59 [95% CI: 0.55&#x02013;12.11]). No stillbirths, therapeutic abortions, ectopic pregnancies and molar pregnancies were reported. At the time of the reported analysis, 2 pregnancies were still ongoing in girls who received HPV-16/18 vaccine.</p><p>Complete pregnancy data from medical birth registries will be available at the time of final analysis.</p></sec></sec><sec sec-type="discussion" id="s0003"><title>Discussion</title><p>Sizeable cluster-randomized phase IV trial cohorts, enrolled in a population-based fashion, are now available for studies on the effectiveness and safety of HPV-16/18 vaccination. These population-based cohorts provide unique health registry-based, quantitative data on the safety of the HPV-16/18 AS04-adjuvanted vaccine and the HBV vaccine. This large community-randomized study assessed the safety of HPV-16/18 vaccination in early adolescents, providing relative risk estimates on the occurrence of NOADs in the 2 vaccine arms over 2&#x02013;3 y of follow-up. We found that the medical record-confirmed IDDM incidence in HPV-16/18 vaccinees was lower than that in HBV vaccinees. The incidence of IDDM seen in HPV-16/18 vaccinees in this study is also lower than that reported in somewhat younger, 10&#x02013;14 year-old Finns (50.4 per 100,000).<xref rid="cit0026" ref-type="bibr"><sup>26</sup></xref> Our observation, and a significantly decreased incidence rate ratio for IDDM (0.55) in approximately 190,000 females that has also been reported following HPV-6/11/16/18 vaccination,<xref rid="cit0027" ref-type="bibr"><sup>27</sup></xref> suggest that the possible role of HPVs in IDDM warrants further investigation. The possibility, that the HPV VLP vaccines and/or the AS04-adjuvant of the HPV-16/18 vaccine provide unexpected protection against IDDM, e.g., by delaying/re-directing an already ongoing autoimmune process, should also be explored.</p><p>As for other NOADs, except those that remained blinded at the time of this analysis, we observed no apparent difference in the incidence of overall medical record-confirmed or possibly related occurrence estimates between the 2 vaccination arms. This is in line with comparable health registry-based findings on the HPV-6/11/16/18 vaccine.<xref rid="cit0028" ref-type="bibr"><sup>28</sup></xref> The health registry-based surveillance was more sensitive than the conventional SAE surveillance. This kind of health registry-based quantitative analysis is an important adjunct to the safety data on the HPV-16/18 vaccine and will in the future continue to be most appealing to health authorities in the context of newly licensed vaccines for suspected or alleged vaccine-associated adverse effects (e.g., autism, narcolepsy) or in the case of HPV vaccination, primary ovarian failure syndrome<xref rid="cit0029" ref-type="bibr"><sup>29</sup></xref> or miscarriage.<xref rid="cit0023" ref-type="bibr"><sup>23,30-32</sup></xref></p><p>Both active and passive safety surveillance in this trial showed that the HPV-16/18 vaccine has an acceptable safety and reactogenicity profile in boys, which is similar to the results of other studies of this vaccine in adolescent girls<xref rid="cit0024" ref-type="bibr"><sup>24,33</sup></xref> and boys.<xref rid="cit0034" ref-type="bibr"><sup>34</sup></xref></p><p>Strengths of our study were uniform enrolment of the early adolescents by school year and birth cohort and community, retaining the participants in the follow-up phase, and population-based health registry follow-up. Analysis of questionnaire data for the study participants showed no differences in behavioral or health conscience characteristics between the 2 vaccine groups.<xref rid="cit0025" ref-type="bibr"><sup>25</sup></xref> The differential blinding used in the study is a potential limitation, mainly for the active surveillance. Other limitations include the imbalance in gender distribution between the 2 vaccine groups (83.6% of vaccinees were female and 16.4% were male in the HPV-16/18 vaccine group compared with 46.8% and 53.2%, respectively, in the HBV vaccine group). In addition, safety data were collected via different methods of surveillance, including active surveillance in a subset of male study participants (using diary cards and phone calls) and surveillance of NOADs in all study participants based on download from the national heath registry (HILMO). The follow-up time for safety endpoints varied for the different surveillance methods and also within subjects for surveillance based on registry download. The HILMO database is one of the most important registers used in healthcare research in Finland.<xref rid="cit0035" ref-type="bibr"><sup>35</sup></xref> This database receives annually (by law) discharge information from all hospitals in the country, including both inpatient and outpatient services. However, it should be noted that the case assessment of HILMO-retrieved NOADs was based on the review of medical records which did not always provide all sufficient information for assessment of autoimmune diseases. Finally, analysis of safety was planned to be descriptive and no correction for multiplicity was applied. Study findings should therefore be interpreted with caution.</p><p>With the current follow-up mode, our community-randomized phase IV trial will continue to provide population-based safety data (e.g. on chronic diseases, pregnancy outcomes) for the HPV-16/18 vaccine.</p></sec><sec sec-type="methods" id="s0004"><title>Materials and methods</title><sec id="s0004-0001"><title>Study design</title><p>This study was conducted in 33 major, non-adjacent Finnish communities as previously described.<xref rid="cit0025" ref-type="bibr"><sup>25</sup></xref> All 80,272 Finnish or Swedish speaking boys and girls in the 1992&#x02013;1995 birth cohorts in these communities were invited by letter to participate in the trial. The communities were stratified into 3 groups according to HPV-16/18 seroprevalence (low, &#x0003c;20.5%; intermediate, 20.5&#x02013;24.0%; high, &#x0003e;24.0%). Within each seroprevalence group, communities were randomly assigned in equal numbers to one of 3 intervention arms using a random number generator. In Arm A communities, 90% of participating girls and boys received HPV-16/18 vaccine and 10% received hepatitis B virus (HBV) vaccine (<italic>Engerix&#x02122; B</italic>, GSK Vaccines); in Arm B communities, 90% of girls received HPV-16/18 vaccine and 10% of girls and 100% of boys received HBV vaccine; in Arm C communities, 100% of girls and boys received HBV vaccine. The 9:1 ratio used to allocate study participants from Arms A (males and females) and B (females only) was determined to target an HPV vaccination coverage of approximately 70% within adolescent resident in these communities, considering that 85&#x02013;90% of study participants would meet admission criteria and that approximately 90% of them would agree to participate in the immunization phase. Treatment allocation at investigator sites was performed using a central internet-based randomization system. Vaccine doses were administered at Months 0, 1 and 6 at schools by the same study nurses during school years 2007&#x02013;2008, 2008&#x02013;2009 and 2009&#x02013;2010. Although the study was open at community level because different vaccination strategies were used between Arms (for primary objectives), blinding was maintained for all subjects in Arm A and for girls in Arm B in order to reduce bias for both safety and effectiveness analysis.</p><p>The study was approved by a regional independent ethics committee and conducted in accordance with good clinical practice (GCP) and all applicable regulatory requirements, including the Declaration of Helsinki. Subjects aged &#x0003c;15&#x000a0;y provided written informed assent prior to the performance of any study-specific procedures; written informed consent was also obtained from participants' parents or legal representatives. Written informed consent was obtained from study participants aged &#x02265;15&#x000a0;years.</p></sec><sec id="s0004-0002"><title>Safety reporting</title><p>A combination of active and passive safety surveillance was performed according to intervention arm (<xref ref-type="fig" rid="f0004">Fig.&#x000a0;4</xref>). As the study was conducted while the HPV-16/18 vaccine was not licensed for use in males, it was designed to provide important safety information in males in order to complement the already substantial safety data available in women. Therefore, a subset of boys from Arm A and Arm C communities was selected for active assessment of safety using diary cards (male diary card subset). The size of the eligible population was the main consideration for the selection of the communities for the diary card subset. These subjects were to record solicited local and general symptoms within 7&#x000a0;d (Days 0&#x02013;6) and unsolicited AEs within 30&#x000a0;d (Days 0&#x02013;29) after each vaccination. The investigator recorded any occurrence of rash and/or urticaria within 30&#x000a0;minutes following each vaccination. These subjects were also actively questioned at Months 7 and 12 about any MSCs (including NOADs) and SAEs that might have occurred after the first vaccination. Active safety surveillance for the occurrence of SAEs was also performed in boys from Arm A communities who were not included in the diary card subset at Months 7 and 12. A SAE was any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability or incapacity, or was a congenital anomaly or birth defect in the offspring of a study participant.
<fig id="f0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>Overview of safety assessments within intervention arms. In Arm A, 90% of boys and girls received HPV-16/18 vaccine and 10% received HBV vaccine. In Arm B, 90% of girls received HPV-16/18 vaccine and 10% of girls and all boys received HBV vaccine. In Arm C, all girls and boys received HBV vaccine. DC, diary card; M, month; MSC, medically significant conditions; NOAD, new-onset autoimmune diseases; PS, passive surveillance including reporting of possibly vaccine-related SAEs and NOADs based on registry download; SAEs, serious adverse events.</p></caption><graphic xlink:href="khvi-12-12-1183847-g004"/></fig>
</p><p>Passive safety surveillance was performed for all subjects in all intervention arms throughout the study period up to the cut-off date for this interim analysis. Any SAEs reported to the investigator considered possibly related to vaccination and pregnancy outcomes were reported using a remote data entry system at the study sites and/or at the junior high-schools. For the HILMO-based analysis (Fig.&#x000a0;S1), the study participants had consented for personal identity code (PIC)-based linkages of the Registry of Vaccinated Individuals (RVI) and the HILMO. The RVI and HILMO registry linkage for predefined NOADs (Table&#x000a0;S3) was performed after the HILMO registry had been completed for the 2010 diagnostic (ICD-10 encoded) data on all outpatient and inpatient visits in Finland. Thus, depending on the time of enrolment, there were approximately 1&#x02013;3&#x000a0;y of registry-based follow-up data available for the different birth cohorts for the predefined NOADs after administration of the first vaccine dose (from October 2007 to December 2010 for the 1992&#x02013;1993 birth cohorts and from August 2008 to December 2010 for the 1994&#x02013;1995 birth cohorts). The HILMO register is virtually complete for all the outpatient and inpatient ICD-10 diagnoses made by Finnish healthcare since 2000 and 1996, respectively.<xref rid="cit0035" ref-type="bibr"><sup>35</sup></xref> The cases identified in the register linkage were confirmed by medical history data, which were obtained based on the informed consent from the hospitals and hospital municipal health centers. The most important consideration for not excluding possible causality was temporal association, namely onset within 18&#x000a0;months from the first vaccine dose (i.e., approximately 12&#x000a0;months from the last vaccine dose). For the NOAD assessment, the investigator was blinded to both vaccination and community status.</p></sec><sec id="s0004-0003"><title>Statistical analyses</title><p>This was a planned interim analysis, which was initiated after completion of the Month 12 active surveillance, and was conducted when Month 12 passive surveillance data for subjects enrolled by the end of 2009 were available. The current report presents the safety data recorded up to April 2011 in all male and female study participants. The primary population for the analysis of safety was the total vaccinated cohort. For the male diary card subset, the overall percentage of doses with any and grade 3 solicited local and general symptoms were calculated. The percentage of subjects with unsolicited AEs (within 30&#x000a0;d following any vaccine dose) and with SAEs, MSCs and NOADs (up to Month 12 after first vaccine dose) were also calculated. For all study participants (active and passive surveillance combined), the incidence rates (per 100,000 person-years) of subjects with at least one report of SAE with relationship to vaccination over the duration of follow-up for this interim analysis, was calculated with exact 95% CI, together with RR (and 95% CI). The incidence rate (per 100,000 person-years) of study participants with at least one report of NOAD classified by MedDRA was calculated with exact 95% CI, together with RR (and 95% CI), both for the entire duration of follow-up for this interim analysis and for the 12-month period after administration of the last vaccine dose. Relative risks (and 95% CI) as well as 95% CIs around frequency of pregnancy outcomes were calculated in a <italic>post-hoc</italic> analysis.</p></sec></sec><sec id="s0005"><title>Trademark statement</title><p><italic>Cervarix</italic> is a registered trademark of the GSK group of companies. <italic>Engerix-B</italic> is a trademark of the GSK group of companies.</p></sec><sec id="s0006"><title>Highlights</title><list list-type="bullet"><list-item><p>As seen in girls, the HPV-16/18 vaccine has acceptable safety/reactogenicity in boys</p></list-item><list-item><p>Similar rates of possibly related serious adverse events for HBV and HPV-16/18 vaccines</p></list-item><list-item><p>Low incidence of insulin-dependent diabetes mellitus seen in HPV-16/18 vaccinees</p></list-item><list-item><p>Small number of cases observed for most other new-onset autoimmune diseases</p></list-item><list-item><p>No apparent differences in incidences of other autoimmune diseases between vaccines</p></list-item></list></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SM5128"><caption><title>Supplemental_Material.zip</title></caption><media xlink:href="khvi-12-12-1183847-s001.zip" mimetype="application" mime-subtype="zip" orientation="portrait" id="d37e246" position="anchor"/></supplementary-material></sec></body><back><sec sec-type="abbreviations"><title>Abbreviations</title><p>
<def-list><def-item><term>AE</term><def><p>adverse event</p></def></def-item><def-item><term>CI</term><def><p>confidence interval</p></def></def-item><def-item><term>CIN</term><def><p>cervical intraepithelial neoplasia</p></def></def-item><def-item><term>HBV</term><def><p>hepatitis B virus</p></def></def-item><def-item><term>HILMO</term><def><p>Care Register for Social Welfare and Health Care</p></def></def-item><def-item><term>HPV</term><def><p>human papillomavirus</p></def></def-item><def-item><term>ICD-10</term><def><p>International Classification of Diseases-10</p></def></def-item><def-item><term>IDDM</term><def><p>insulin-dependent diabetes mellitus</p></def></def-item><def-item><term>JA</term><def><p>juvenile arthritis</p></def></def-item><def-item><term>MPL</term><def><p>3-<italic>O</italic>-desacyl-4&#x02032;-monophosphoryl lipid A</p></def></def-item><def-item><term>MSC</term><def><p>medically significant condition</p></def></def-item><def-item><term>NOAD</term><def><p>new-onset autoimmune disease</p></def></def-item><def-item><term>pIMD</term><def><p>potential immune-mediated disease</p></def></def-item><def-item><term>RR</term><def><p>relative risk</p></def></def-item><def-item><term>SAE</term><def><p>serious adverse event</p></def></def-item><def-item><term>VE</term><def><p>vaccine efficacy</p></def></def-item><def-item><term>VLP</term><def><p>virus-like particle</p></def></def-item></def-list></p></sec><sec><title>Disclosure of potential conflicts of interest</title><p>Matti Lehtinen, Dan Apter and Jorma Paavonen have received grants from Merck &#x00026; Co. Inc., and from the GSK group of companies for their HPV vaccination studies through their employers: University of Tampere, Family Federation of Finland and University of Helsinki, respectively. Maria-Genalin Angelo, Julia Zima, Marie-Pierre David, Sanjoy Datta, Dan Bi and Frank Struyf are employees of the GSK group of companies. Gary Dubin was employed by the GSK group of companies at the time of the study and has several relevant patents and stock shares from the GSK group of companies. He is currently a full time employee of Takeda Pharmaceuticals (Deerfield, Illinois) and receives salary and stock shares. Maria-Genalin Angelo, Julia Zima, Marie-Pierre David, Sanjoy Datta, Dan Bi and Frank Struyf receive stock options/shares from the GSK group of companies. Tiina Eriksson, Kari Natunen, Eero Pukkala and Mari Hokkanen have no potential conflicts of interest to declare.</p></sec><sec><title>Acknowledgments</title><p>The devoted, high-quality work of the 85 study nurses responsible for the trial recruitment and follow-up has been invaluable. The authors acknowledge the principal investigators for their contribution to the study, the contributors at the University of Tampere, the support of the Finnish GSK Vaccines team headed by Ulpu Andersson, Maaria Soila and Markku Pulkkinen, as well as Dominique Descamps, Kurt Dobbelaere, Annamarie Camier and Nele Martens at GSK Vaccines, and Issam Jamiai (4Clinics on behalf of GSK Vaccines). Jennifer Coward (independent medical writer) provided editorial assistance and Stephanie Delval (XPE Pharma &#x00026; Science) provided publication coordination on behalf of GSK Vaccines.</p></sec><sec><title>Funding</title><p>GlaxoSmithKline Biologicals SA was the funding source and was involved in all stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA also took responsibility for all costs associated with the development and publishing of the present manuscript. All authors participated in the design or implementation or analysis, and interpretation of the study and in the development of this manuscript. All authors had full access to the data and gave final approval before submission. The corresponding author was responsible for submission of the publication.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>EMA</collab></person-group>
<article-title>Gardasil European Public Assessment Report (EMEA/H/C/000703)</article-title>; <month>9</month>
<year>2006</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp</ext-link></mixed-citation></ref><ref id="cit0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>EMA</collab></person-group>
<article-title>Cervarix European Public Assessment Report (EMEA/H/C/000721)</article-title>; <month>9</month>
<year>2007</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&#x00026;mid=WC0b01ac058001d124">http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&#x00026;mid=WC0b01ac058001d124</ext-link></mixed-citation></ref><ref id="cit0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dunne</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Saraiya</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lawson</surname><given-names>HW</given-names></name>, <name name-style="western"><surname>Chesson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>ER</given-names></name>; <collab>Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP)</collab></person-group>. <article-title>Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices</article-title>. <source>MMWR Recomm Rep</source>
<year>2007</year>; <volume>56</volume>:<fpage>1</fpage>-<lpage>24</lpage>; PMID:17380109<pub-id pub-id-type="pmid">17380109</pub-id></mixed-citation></ref><ref id="cit0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>FDA</collab></person-group>
<article-title>FDA approves new vaccine for prevention of cervical cancer</article-title>; <month>10</month>
<year>2009</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187048.htm</ext-link></mixed-citation></ref><ref id="cit0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>FDA</collab></person-group>
<article-title>FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV</article-title>; <month>12</month>
<year>2014</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm</ext-link></mixed-citation></ref><ref id="cit0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petrosky</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bocchini</surname><given-names>JA</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Hariri</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chesson</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Saraiya</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Unger</surname><given-names>ER</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></name>; <collab>Centers for Disease Control and Prevention (CDC)</collab></person-group>. <article-title>Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>
<year>2015</year>; <volume>64</volume>:<fpage>300</fpage>-<lpage>4</lpage>; PMID:25811679<pub-id pub-id-type="pmid">25811679</pub-id></mixed-citation></ref><ref id="cit0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paavonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jenkins</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Naud</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Salmeron</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wheeler</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Apter</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Kitchener</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Castellsague</surname><given-names>X</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Efficacy of a prophylactic adjuvanted L1 VLP vaccine against infection with HPV16 and 18 in young women: an interim analysis of a phase III double-blind, randomized controlled trial</article-title>. <source>Lancet</source>
<year>2007</year>; <volume>369</volume>:<fpage>2161</fpage>-<lpage>70</lpage>; PMID:17602732; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S0140-6736(07)60946-5</pub-id><pub-id pub-id-type="pmid">17602732</pub-id></mixed-citation></ref><ref id="cit0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The Future II Study Group</collab></person-group>. <article-title>Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions</article-title>. <source>NEJM</source>
<year>2007</year>; <volume>356</volume>:<fpage>1915</fpage>-<lpage>27</lpage>; PMID:17494925; http://dx.doi.org/<pub-id pub-id-type="doi">10.1056/NEJMoa061741</pub-id><pub-id pub-id-type="pmid">17494925</pub-id></mixed-citation></ref><ref id="cit0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehtinen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Dillner</surname><given-names>J</given-names></name></person-group>. <article-title>Clinical trials of human papillomavirus vaccines and beyond</article-title>. <source>Nat Rev Clin Oncol</source>
<year>2013</year>; <volume>10</volume>:<fpage>400</fpage>-<lpage>10</lpage>; PMID:23736648; http://dx.doi.org/<pub-id pub-id-type="doi">10.1038/nrclinonc.2013.84</pub-id><pub-id pub-id-type="pmid">23736648</pub-id></mixed-citation></ref><ref id="cit0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehtinen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Herrero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mayaud</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Barnabas</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Dillner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Paavonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>PG</given-names></name></person-group>. <article-title>Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries</article-title>. <source>Vaccine</source>
<year>2006</year>; <volume>24</volume>(<issue>Suppl 3</issue>):<fpage>S3/233-41</fpage>; PMID:16950012; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2006.05.109</pub-id><pub-id pub-id-type="pmid">16950012</pub-id></mixed-citation></ref><ref id="cit0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rana</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huhtala</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Apter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Eriksson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Luostarinen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Natunen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Paavonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Pukkala</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lehtinen</surname><given-names>M</given-names></name></person-group>. <article-title>Understanding of long-term protection of human papillomavirus vaccination against cervical carcinoma</article-title>. <source>Int J Cancer</source>
<year>2013</year>; <volume>132</volume>:<fpage>2833</fpage>-<lpage>8</lpage>; PMID:23180157; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/ijc.27971</pub-id><pub-id pub-id-type="pmid">23180157</pub-id></mixed-citation></ref><ref id="cit0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>European Cervical Cancer Association</collab></person-group>
<article-title>HPV vaccination across Europe</article-title>; <year>2009</year> Available at: <ext-link ext-link-type="uri" xlink:href="http://www.ecca.info/fileadmin/user_upload/Reports/HPV_Vaccination_across_Europe.pdf">http://www.ecca.info/fileadmin/user_upload/Reports/HPV_Vaccination_across_Europe.pdf</ext-link></mixed-citation></ref><ref id="cit0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Tsu</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Deeks</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Cubie</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Vicari</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Brotherton</surname><given-names>JM</given-names></name></person-group>. <article-title>Human papillomavirus vaccine introduction &#x02013; the five first years</article-title>. <source>Vaccine</source>
<year>2012</year>; <volume>30</volume>(<issue>suppl 5</issue>):<fpage>F139</fpage>-<lpage>48</lpage>; PMID: 23199957; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.05.039</pub-id><pub-id pub-id-type="pmid">23199957</pub-id></mixed-citation></ref><ref id="cit0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brotherton</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Fridman</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>May</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Chapell</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Saville</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Gertig</surname><given-names>DM</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Early effect of HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study</article-title>. <source>Lancet</source>
<year>2011</year>; <volume>377</volume>:<fpage>2085</fpage>-<lpage>92</lpage>; PMID:21684381; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S0140-6736(11)60551-5</pub-id><pub-id pub-id-type="pmid">21684381</pub-id></mixed-citation></ref><ref id="cit0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herrero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gonz&#x000e1;lez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></name></person-group>. <article-title>Present status of human papillomavirus vaccine development and implementation</article-title>. <source>Lancet Oncol</source>
<year>2015</year>; <volume>16</volume>:<fpage>e206</fpage>-<lpage>16</lpage>; PMID:25943065; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S1470-2045(14)70481-4</pub-id><pub-id pub-id-type="pmid">25943065</pub-id></mixed-citation></ref><ref id="cit0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gar&#x000e7;on</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Morel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wettendorff</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Van Mechelen</surname><given-names>M</given-names></name></person-group>. <article-title>Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach</article-title>. <source>BioDrugs</source>
<year>2011</year>; <volume>25</volume>:<fpage>217</fpage>-<lpage>26</lpage>; PMID:21815697; http://dx.doi.org/<pub-id pub-id-type="doi">10.2165/11591760-000000000-00000</pub-id><pub-id pub-id-type="pmid">21815697</pub-id></mixed-citation></ref><ref id="cit0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wheeler</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Castellsague</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Garland</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Szarewski</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Paavonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Naud</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Salmer&#x000f3;n</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Apter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kitchener</surname><given-names>H</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Cross-protective efficacy of the HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial</article-title>. <source>Lancet Oncol</source>
<year>2012</year>; <volume>13</volume>:<fpage>100</fpage>-<lpage>10</lpage>; PMID:22075170; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S1470-2045(11)70287-X</pub-id><pub-id pub-id-type="pmid">22075170</pub-id></mixed-citation></ref><ref id="cit0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malag&#x000f3;n</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Drolet</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Boily</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Franco</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Jit</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brisson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Brisson</surname><given-names>M</given-names></name></person-group>. <article-title>Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>
<year>2012</year>; <volume>12</volume>:<fpage>781</fpage>-<lpage>9</lpage>; PMID:22920953; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S1473-3099(12)70187-1</pub-id><pub-id pub-id-type="pmid">22920953</pub-id></mixed-citation></ref><ref id="cit0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Medina</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Valencia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>TY</given-names></name>, <name name-style="western"><surname>Behre</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Catteau</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name></person-group>. <article-title>Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14&#x000a0;years</article-title>. <source>J Adolesc Health</source>
<year>2012</year>; <volume>50</volume>:<fpage>187</fpage>-<lpage>94</lpage>; PMID:22265115; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.jadohealth.2011.11.004</pub-id><pub-id pub-id-type="pmid">22265115</pub-id></mixed-citation></ref><ref id="cit0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmeink</surname><given-names>CE</given-names></name>, <name name-style="western"><surname>Bekkers</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Josefsson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Richardus</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Berndtsson Blom</surname><given-names>K</given-names></name>, <name name-style="western"><surname>David</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Dobbelaere</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name></person-group>. <article-title>Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls</article-title>. <source>Vaccine</source>
<year>2011</year>; <volume>29</volume>:<fpage>9276</fpage>-<lpage>83</lpage>; PMID:21856349; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2011.08.037</pub-id><pub-id pub-id-type="pmid">21856349</pub-id></mixed-citation></ref><ref id="cit0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Verstraeten</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name>, <name name-style="western"><surname>David</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Zahaf</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hardt</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Izurieta</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Dubin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Breuer</surname><given-names>T</given-names></name></person-group>. <article-title>Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines</article-title>. <source>Vaccine</source>
<year>2008</year>; <volume>26</volume>:<fpage>6630</fpage>-<lpage>8</lpage>; PMID:18845199; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.09.049</pub-id><pub-id pub-id-type="pmid">18845199</pub-id></mixed-citation></ref><ref id="cit0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hardt</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Spiessens</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Izurieta</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Verstraeten</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Breuer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Dubin</surname><given-names>G</given-names></name></person-group>. <article-title>Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention. A pooled analysis of 11 clinical trials</article-title>. <source>Hum Vaccin</source>
<year>2009</year>; <volume>5</volume>:<fpage>332</fpage>-<lpage>40</lpage>; PMID:19022320; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2008.10.088</pub-id><pub-id pub-id-type="pmid">19221517</pub-id></mixed-citation></ref><ref id="cit0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelo</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>David</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Zima</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Baril</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Dubin</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Arellano</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Struyf</surname><given-names>F</given-names></name></person-group>. <article-title>Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme</article-title>. <source>Pharmacoepidemiol Drug Saf</source>
<year>2014</year>; <volume>23</volume>:<fpage>466</fpage>-<lpage>79</lpage>: PMID:24644063; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/pds.3554</pub-id><pub-id pub-id-type="pmid">24644063</pub-id></mixed-citation></ref><ref id="cit0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angelo</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Zima</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tavares Da Silva</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Baril</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Arellano</surname><given-names>F</given-names></name></person-group>. <article-title>Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4&#x02009;years of experience</article-title>. <source>Pharmacoepidemiol Drug Saf</source>
<year>2014</year>; <volume>23</volume>:<fpage>456</fpage>-<lpage>65</lpage>; PMID:24644078; http://dx.doi.org/<pub-id pub-id-type="doi">10.1002/pds.3593</pub-id><pub-id pub-id-type="pmid">24644078</pub-id></mixed-citation></ref><ref id="cit0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lehtinen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Apter</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Baussano</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Eriksson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Natunen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Paavonen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>V&#x000e4;nsk&#x000e4;</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>David</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Datta</surname><given-names>S</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Characteristics of a cluster-randomized phase IV human papillomavirus vaccination effectiveness trial</article-title>. <source>Vaccine</source>
<year>2015</year>; <volume>33</volume>:<fpage>1284</fpage>-<lpage>90</lpage>; PMID:25593103; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2014.12.019</pub-id><pub-id pub-id-type="pmid">25593103</pub-id></mixed-citation></ref><ref id="cit0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harjutsalo</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Sj&#x000f6;berg</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Tuomilehto</surname><given-names>J</given-names></name></person-group>. <article-title>Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study</article-title>. <source>Lancet</source>
<year>2008</year>; <volume>371</volume>:<fpage>1777</fpage>-<lpage>82</lpage>; PMID:8502302; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/S0140-6736(08)60765-5</pub-id><pub-id pub-id-type="pmid">18502302</pub-id></mixed-citation></ref><ref id="cit0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chao</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Klein</surname><given-names>NP</given-names></name>, <name name-style="western"><surname>Velicer</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Sy</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Slezak</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Takhar</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ackerson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Cheetham</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Deosaransingh</surname><given-names>K</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Surveillance of autoimmune conditions following routine use of quadrivalent papillomavirus vaccine</article-title>. <source>J Intern Med</source>
<year>2012</year>; <volume>271</volume>:<fpage>193</fpage>-<lpage>203</lpage>; PMID:21973261; http://dx.doi.org/<pub-id pub-id-type="doi">10.1111/j.1365-2796.2011.02467.x</pub-id><pub-id pub-id-type="pmid">21973261</pub-id></mixed-citation></ref><ref id="cit0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arnheim-Dahlstr&#x000f6;m</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pasternak</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Svanstr&#x000f6;m</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Spar&#x000e9;n</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Hviid</surname><given-names>A</given-names></name></person-group>. <article-title>Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study</article-title>. <source>BMJ</source>
<year>2013</year>; <volume>347</volume>:<fpage>f5906</fpage>; PMID:24108159; http://dx.doi.org/<pub-id pub-id-type="doi">10.1136/bmj.f5906</pub-id><pub-id pub-id-type="pmid">24108159</pub-id></mixed-citation></ref><ref id="cit0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruber</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>. <article-title>A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis</article-title>. <source>Curr Opin Obstet Gynecol</source>
<year>2015</year>; <volume>27</volume>:<fpage>265</fpage>-<lpage>70</lpage>; PMID:26125978; http://dx.doi.org/<pub-id pub-id-type="doi">10.1097/GCO.0000000000000183</pub-id><pub-id pub-id-type="pmid">26125978</pub-id></mixed-citation></ref><ref id="cit0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacholder</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>BE</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Macones</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Befano</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hildesheim</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Rodr&#x000ed;guez</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Solomon</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Herrero</surname><given-names>R</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials</article-title>. <source>BMJ</source>
<year>2010</year>; <volume>340</volume>:<fpage>c712</fpage>; PMID:20197322<pub-id pub-id-type="pmid">20197322</pub-id></mixed-citation></ref><ref id="cit0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panagiotou</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Befano</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Rodr&#x000ed;guez</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Herrero</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schiller</surname><given-names>JT</given-names></name>, <name name-style="western"><surname>Kreimer</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Schiffman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hildesheim</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wilcox</surname><given-names>AJ</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial</article-title>. <source>BMJ</source>
<year>2015</year>; <volume>351</volume>:<fpage>h4358</fpage>; PMID:26346155; http://dx.doi.org/<pub-id pub-id-type="doi">10.1136/bmj.h4358</pub-id><pub-id pub-id-type="pmid">26346155</pub-id></mixed-citation></ref><ref id="cit0032"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baril</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Rosillon</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Willame</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Angelo</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Zima</surname><given-names>J</given-names></name>, <name name-style="western"><surname>van den Bosch</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Van Staa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Boggon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bunge</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Hernandez-Diaz</surname><given-names>S</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Risk of spontaneous abortion and other pregnancy outcomes in 15-25 year old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom</article-title>. <source>Vaccine</source>
<year>2015</year>; <volume>33</volume>:<fpage>6884</fpage>-<lpage>91</lpage>; PMID:26206268; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.vaccine.2015.07.024</pub-id><pub-id pub-id-type="pmid">26206268</pub-id></mixed-citation></ref><ref id="cit0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Medina</surname><given-names>DM</given-names></name>, <name name-style="western"><surname>Valencia</surname><given-names>A</given-names></name>, <name name-style="western"><surname>de Velasquez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Prymula</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Garc&#x000ed;a-Sicilia</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rombo</surname><given-names>L</given-names></name>, <name name-style="western"><surname>David</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Descamps</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Hardt</surname><given-names>K</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls</article-title>. <source>J Adolesc Health</source>
<year>2010</year>; <volume>46</volume>:<fpage>414</fpage>-<lpage>21</lpage>; PMID:20413076; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.jadohealth.2010.02.006</pub-id><pub-id pub-id-type="pmid">20413076</pub-id></mixed-citation></ref><ref id="cit0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pet&#x000e4;j&#x000e4;</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ker&#x000e4;nen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Karppa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Kawa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lantela</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Siitari-Mattila</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lev&#x000e4;nen</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tocklin</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Godeaux</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Lehtinen</surname><given-names>M</given-names></name>, et&#x000a0;al.</person-group>
<article-title>Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18&#x000a0;years</article-title>. <source>J Adolesc Health</source>
<year>2009</year>; <volume>44</volume>:<fpage>33</fpage>-<lpage>40</lpage>; PMID:19101456; http://dx.doi.org/<pub-id pub-id-type="doi">10.1016/j.jadohealth.2008.10.002</pub-id><pub-id pub-id-type="pmid">19101456</pub-id></mixed-citation></ref><ref id="cit0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>HILMO</collab></person-group>
<article-title>Sosiaalihuollon- ja terveydenhuollon hoitoilmoitus. Ohjeita ja luokituksia</article-title>. <source>Stakes</source>
<year>2006</year>; <volume>2</volume>:<fpage>1</fpage>-<lpage>75</lpage>; [Article in Finnish].</mixed-citation></ref></ref-list></back></article>